Phenotypic characterization of circulating lung cancer cells for clinically actionable targets
Kulasinghe A., Kapeleris J., Cooper C., Ibragimi V. M. M., O’Byrne K., Punyadeera C.
Cancers
Vol.11, Issue3, Num.380
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.3390/cancers11030380
Аннотация:
Abstract: Objectives: In non-small cell lung cancers (NSCLC), tumour biopsy can often be an invasive procedure. The development of a non-invasive methodology to study genetic changes via circulating tumour cells (CTCs) is an appealing concept. Whilst CTCs typically remain as rare cells, improvements in epitope-independent CTC isolation techniques has given rise to a greater capture of CTCs. In this cross sectional study, we demonstrate the capture and characterization of NSCLC CTCs for the clinically actionable markers epidermal growth factor receptor (EGFR) alterations, anaplastic lymphoma kinase (ALK) rearrangements and programmed death ligand-1 (PD-L1) expression. The study identified CTCs/CTC clusters in 26/35 Stage IV NSCLC patients, and subsequently characterized the CTCs for EGFR mutation, ALK status and PD-L1 status. This pilot study demonstrates the potential of a non-invasive fluid biopsy to determine clinically relevant biomarkers in NSCLC. © 2019 by the authors. Licensee MD
Ключевые слова:
Actionable mutations; Circulating tumour cells; Liquid biopsy; Non-small cell lung cancer
anaplastic lymphoma kinase; epidermal growth factor receptor; programmed death 1 ligand 1; adult; aged; ALK gene; Article; cancer cell; cancer staging; cell isolation; cell selection; circulating tumor cell; clinical article; cohort analysis; controlled study; cross-sectional study; DNA hybridization; EGFR gene; exon; female; fluorescence in situ hybridization; gene deletion; gene expression; gene mutation; gene rearrangement; gene targeting; human; human cell; hydrodynamics; liquid biopsy; male; microfluidic analysis; non small cell lung cancer; PD L1 gene; phenotype; pilot study; very elderly
Язык текста: Английский
ISSN: 2072-6694
Kulasinghe A.
Kapeleris J.
Cooper C.
Ibragimi V. M. M. Varkiani Madzhid Modzhtaba 1983-
O’Byrne K.
Punyadeera C.
Куласингхе А.
Капелерис Й.
Cоопер C.
Ибрагими В. М. М. Варкиани Маджид Моджтаба 1983-
О’Бyрне К.
Пунядеера C.
Phenotypic characterization of circulating lung cancer cells for clinically actionable targets
Текст визуальный непосредственный
Cancers
Vol.11, Issue3 Num.380
2019
Статья
Actionable mutations Circulating tumour cells Liquid biopsy Non-small cell lung cancer
anaplastic lymphoma kinase epidermal growth factor receptor programmed death 1 ligand 1 adult aged ALK gene Article cancer cell cancer staging cell isolation cell selection circulating tumor cell clinical article cohort analysis controlled study cross-sectional study DNA hybridization EGFR gene exon female fluorescence in situ hybridization gene deletion gene expression gene mutation gene rearrangement gene targeting human human cell hydrodynamics liquid biopsy male microfluidic analysis non small cell lung cancer PD L1 gene phenotype pilot study very elderly
Abstract: Objectives: In non-small cell lung cancers (NSCLC), tumour biopsy can often be an invasive procedure. The development of a non-invasive methodology to study genetic changes via circulating tumour cells (CTCs) is an appealing concept. Whilst CTCs typically remain as rare cells, improvements in epitope-independent CTC isolation techniques has given rise to a greater capture of CTCs. In this cross sectional study, we demonstrate the capture and characterization of NSCLC CTCs for the clinically actionable markers epidermal growth factor receptor (EGFR) alterations, anaplastic lymphoma kinase (ALK) rearrangements and programmed death ligand-1 (PD-L1) expression. The study identified CTCs/CTC clusters in 26/35 Stage IV NSCLC patients, and subsequently characterized the CTCs for EGFR mutation, ALK status and PD-L1 status. This pilot study demonstrates the potential of a non-invasive fluid biopsy to determine clinically relevant biomarkers in NSCLC. © 2019 by the authors. Licensee MD